SAN DIEGO, May 4, 2026 /PRNewswire/ — Biotheryx, Inc., a biopharmaceutical company focused on the discovery and development of first-in-class protein degraders for cancer and inflammatory diseases, today announced that data from its Phase 1A Dose Escalation Study of BTX-9341, a potent…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
